|Bid||160.15 x 100|
|Ask||220.00 x 200|
|Day's range||176.83 - 180.91|
|52-week range||161.09 - 209.22|
|PE ratio (TTM)||181.72|
|Dividend & yield||0.91 (0.51%)|
|1y target est||242.49|
BioCryst's oral hereditary angioedema drug candidate hit the mark in a second interim analysis.
LEXINGTON, Massachusetts, May 25, 2017 /PRNewswire/ -- Shire plc (LSE: SHP, NASDAQ: SHPG) announces that Flemming Ornskov, MD, Chief Executive Officer, will participate at the Jefferies Healthcare Conference ...
The FDA has accepted Ultragenyx Pharmaceutical Inc. (RARE)'s BLA for rhGUS on a priority review basis and set a PDUFA action date of Nov 16, 2017.